Literature DB >> 21897604

Re: Heparin-induced thrombocytopenia - Type 2.

Vipul D Yagnik1.   

Abstract

Entities:  

Year:  2011        PMID: 21897604      PMCID: PMC3159255          DOI: 10.4103/0973-6247.83254

Source DB:  PubMed          Journal:  Asian J Transfus Sci        ISSN: 0973-6247


× No keyword cloud information.
Sir, I read an article entitled “Heparin-induced thrombocytopenia (HIT) – Type 2”[1] with interest. I would like to congratulate author for his effort to concise such a topic in a nice manner. However, I would like to add few more information regarding this entity which you may find useful [Table 1].
Table 1

Features of HIT

Features of HIT Pretest probability is calculated on the basis of 4Ts: Thrombocytopenia, timing of thrombocytopenia, thrombosis, other cause of thrombocytopenia. Probability is high if more than 50% drop in platelet count after 5 days of initiation of heparin and new development of thrombosis with no other cause for thrombocytopenia. I would like to summarize the treatment for HIT: Stop heparin, postpone warfarin until substantial recovery in platelet count, avoid platelet transfusions,[3] start alternative anticoagulants like lepirudin and argatroban (direct thrombin inhibitor), danaparoid, or fondaparinux (factor Xa inhibitor). Fondaparinux is a synthetic heparin pentasaccharide which does not cross-react with HIT antibodies and can be used for the treatment of HIT.[4]
  4 in total

Review 1.  Heparin-induced thrombocytopenia: diagnosis and management.

Authors:  Theodore E Warkentin
Journal:  Circulation       Date:  2004-11-02       Impact factor: 29.690

2.  Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux.

Authors:  Kevin H M Kuo; Michael J Kovacs
Journal:  Thromb Haemost       Date:  2005-05       Impact factor: 5.249

3.  Heparin induced thrombocytopenia-type 2.

Authors:  Tanveer A Majeed
Journal:  Asian J Transfus Sci       Date:  2010-07

4.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

Authors:  T E Warkentin; M N Levine; J Hirsh; P Horsewood; R S Roberts; M Gent; J G Kelton
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.